(The currency was clarified in the last paragraph
for dollars rpt dollars.)
NEW YORK (dpa-AFX) – The number of strokes when speculating about a
Bayer pharma and agricultural chemicals group soon to reach agreement
in the US glyphosate dispute is higher: reported
Bloomberg news agency on Thursday evening citing
persons familiar with the settlement negotiations that lawyers
some plaintiffs with Bayer about a settlement against the payment of
negotiated a total of $ 10 billion.
Only last week had the legal conflict
Alleged cancer risks of weed killers with the active ingredient
Mediator mediator Ken Feinberg “behaved”
optimistic “showed that within about a month
Agreement could be reached. The Bayer share price rose on
Friday significantly.
In some discussions, Bayer lawyers said the company
going to be eight billion dollars for solving the current cases
put aside and reserve two billion for future lawsuits,
Bloomberg continued. According to the circles, the total stands
but not yet fixed and could change in the course of the talks.
A Bayer spokesman did not want the volume mentioned
express. He emphasized to the financial news agency dpa-AFX
but that mediation is “conscientious and goal-oriented”
will continue. There is no schedule like that
Certainty for success.
Bayer’s shareholders nevertheless distributed a few
Advance praise. The share price rose on Friday morning as
one of the strongest Dax -Values by more than three
Percent to 76.49 euros. With this, the papers continued their recovery
past months after being in the wake of the June 2019
Glyphosate litigation to a multi-year low of around 52
Euros had fallen.
Bayer had the $ 60 billion purchase in 2018
of the US seed giant Monsanto brought immense legal risks into the house.
The first three US lawsuits allegedly carcinogenic
Monsanto’s weed killers had been lost to Bayer and high
Damage judgments collected. The group has the guilty verdicts
however contested and last received an appeal
Support from the United States government, whose environmental agency EPA
Controversial plant poison does not classify glyphosate as carcinogenic.
Most analysts expect the group to be short or short
long on a billion dollar comparison with the numerous
Plaintiffs in the United States agreed. Those responsible also insist on this
Courts.
In the event of an agreement, numerous analysts see – depending on the amount
the amount of compensation to the plaintiffs – still clear air for the
Share price. This is what Alistair Campbell from the investment company Liberum appreciated
a week ago that is still a burden of around 25
Billion euros are priced in the share price, which could be more
as Bayer would probably want to pay in the end and maybe will.
According to analyst Daniel Wendorff from Commerzbank
would reach an agreement in the area of around 10 billion among investors
Dollar will probably be well received, although of course it depends on the
Details would arrive. In addition, investors now wanted the topic
finally get off the table./mis/he/jha/
ISIN DE000BAY0017
AXC0132 2020-01-24 / 11:31
Copyright APA / dpa-AFX. All rights reserved. Redistribution, republication or permanent storage without the express prior consent of APA / dpa-AFX is not permitted.
– ,
